Skip to main content
Clinical Trials/NCT01390532
NCT01390532
Unknown
N/A

Left Ventricular Dyssynchrony: Rest/Stress 3D Blood-Pool Gated D-SPECT Quantification With a High-Speed Dedicated Cardiac Camera Before CRT

University Hospital, Clermont-Ferrand1 site in 1 country30 target enrollmentAugust 2010

Overview

Phase
N/A
Intervention
Not specified
Conditions
Left Ventricular Dyssynchrony
Sponsor
University Hospital, Clermont-Ferrand
Enrollment
30
Locations
1
Primary Endpoint
Left ventricular phase standard deviation.
Last Updated
14 years ago

Overview

Brief Summary

Cardiac Resynchronization Therapy (CRT) is an established treatment for patients with advanced heart failure and left ventricular dyssynchrony (LVD). Too many patients do not clinically improve with CRT. New LVD markers other than QRS duration are needed.

Study objective : feasibility assessment of rest and real-time stress 3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel) to quantify LVD.

Detailed Description

Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (\>85% PHR). Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA).

Registry
clinicaltrials.gov
Start Date
August 2010
End Date
October 2011
Last Updated
14 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
University Hospital, Clermont-Ferrand

Eligibility Criteria

Inclusion Criteria

  • Chronic heart failure with LVEF \< 35 %, QRS \> 120 ms, NYHA III/IV, optimal medical therapy for more than one month.
  • Patient with stable hemodynamic for more than one month,
  • More than 18-year old man or woman,
  • Patient having given his free, inform and signed consent,
  • Patient place setting by the social security system,

Exclusion Criteria

  • Psychiatric disorder
  • Any contra-indication to Technetium,
  • Any contra-indication to dobutamin or atropin
  • Personal or family history of sudden death
  • Previous severe ventricular arrhythmia
  • Obstructive cardiomyopathy, severe aortic stenosis,
  • Pulmonary hypertension,
  • History of renal, lung, hepatic, cardiac transplantation,
  • Pregnant or breast-feeding Woman,
  • Patient who can not conform to the requirements of the protocol,

Outcomes

Primary Outcomes

Left ventricular phase standard deviation.

Secondary Outcomes

  • Left ventricular entropy
  • Left ventricle ejection fraction
  • Quality of life.
  • 6-minutes walking test

Study Sites (1)

Loading locations...

Similar Trials